Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    An Enquiry

    Menu

    Zilebesiran

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Data Support Vutrisiran In ATTR-CM Zilebesiran HTN Management
    Data Support Vutrisiran In ATTR-CM Zilebesiran HTN Management

    30 Mar 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260330643261/en/New-Data-Presented-at-ACC.26-Further-Support-Benefits-of-Vutrisiran-in-ATTR-CM-and-Potential-of-Zilebesiran-for-Hypertension-Management

    BUSINESSWIRE
    30 Mar 2026
    Share Share
    Alnylam Doses First Patient in Ph3 ZENITH Zilebesiran Trial
    Alnylam Doses First Patient in Ph3 ZENITH Zilebesiran Trial

    01 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251001569564/en/Alnylam-Announces-First-Patient-Dosed-in-ZENITH-Global-Phase-3-Cardiovascular-Outcomes-Trial-of-Zilebesiran

    BUSINESSWIRE
    01 Oct 2025
    Share Share
    Roche, Alnylam to Initiate Phase 3 Trial of Zilebesiran
    Roche, Alnylam to Initiate Phase 3 Trial of Zilebesiran

    31 Aug 2025

    // PRESS RELEASE

    https://www.roche.com/media/releases/med-cor-2025-08-30

    PRESS RELEASE
    31 Aug 2025
    Share Share
    Chugai in-licenses RNAi therapeutic zilebesiran for hyp.high cardiovascular risk
    Chugai in-licenses RNAi therapeutic zilebesiran for hyp.high cardiovascular risk

    20 Apr 2024

    // PHARMABIZ

    https://www.pharmabiz.com/NewsDetails.aspx?aid=168662&sid=2

    PHARMABIZ
    20 Apr 2024
    Share Share
    Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran
    Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran

    07 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240407631982/en

    BUSINESSWIRE
    07 Apr 2024
    Share Share
    Alnylam to Webcast to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran
    Alnylam to Webcast to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran

    20 Mar 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240320967622/en

    BUSINESSWIRE
    20 Mar 2024
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.